Evidence map›Paper›PMID 32898554›Full record

ArticleExperimental cell research2020

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.

Yige Fu, Drishti Rathod, Ketan Patel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Immunotherapy and delivery systems for melanoma.Human vaccines & immunotherapeutics · 2024
    Review
  16. Article
  17. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yige FuCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
Drishti RathodCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
Ketan PatelCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA. Electronic address: patelk2@stjohns.edu.
St. John's University · US

Funding

Oral nanoformulation for the treatment of BRAF inhibitor resistant melanomaSC2GM130478 · NIGMS · ST. JOHN'S UNIVERSITY · PI PATEL, KETANKUMAR D. · 2020 to 2021
$328k
NIGMS NIH HHS SC2 GM130478
6 · The paper itself

Abstract

Limited treatment options and development of resistance to targeted therapy within few months pose significant challenges in the treatment of BRAF-mutated malignant melanoma. Moreover, extensive angiogenesis and vasculogenic mimicry promote the rapid progression of disease. The purpose of this study was to develop a protein kinase C inhibitor anchored BRD4 PROTAC (ARV) loaded PEGylated nanoliposomes (LARPC). Palmitoyl-dl-carnitine chloride (PC) was used as a protein kinase C inhibitor to provide a cationic surface charge to LARPC. The formulation was characterized for particle size, zeta potential, drug release and various cell culture assays using HUVEC and vemurafenib resistant melanoma cells. The particle size of LARPC was found to be 105.25 ± 2.76 nm with a zeta potential of +26.6 ± 6.25 mV. Inhibition of angiogenesis was demonstrated by ARV and LARPC using human umbilical vein endothelial cells (HUVEC)-based matrigel basement membrane model. Additionally, LARPC demonstrated very low IC

Indexed as

Antineoplastic AgentsCell Cycle ProteinsDrug Resistance, NeoplasmLiposomesMelanocytesProtein Kinase CTranscription FactorsVemurafenibBromodomain Containing ProteinsCell Line, TumorGene Expression Regulation, NeoplasticHumansHuman Umbilical Vein Endothelial CellsModels, BiologicalMutationNanocapsulesAntineoplastic AgentsBRAF protein, humanBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsLiposomesNanocapsulesPalmitoylcarnitinePolyethylene GlycolsProtein Kinase CProto-Oncogene Proteins B-rafTranscription FactorsVemurafenibARVPalmitoyl-dl-Carnitine chloridePEGylated nanoliposomesProtein kinase C inhibitorVemurafenib-resistant melanoma

Identifiers

PMID32898554
PMCPMC12045034
OpenAlexW3083355994

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.